Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Relationships among the complement, kinin, coagulation, and fibrinolytic systems

  • 103 Accesses

  • 25 Citations

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Accini L, Dixon FJ (1979) Degenerative vascular disease and myocardial infarction in mice with lupus-like syndrome. Am J Pathol 96: 477

  2. 2.

    Aoki N, von Kaulla KN (1969) Inactivation of human serum plasminogen antiactivator by synthetic fibrinolysis inducers. Thromb Diath Haemorrh 22: 251

  3. 3.

    Arroyave CM, Müller-Eberhard HJ (1973) Interactions between human C5, C6, and C7 and their functional significance in complement-dependent cytolysis. J Immunol 111: 536

  4. 4.

    Astrup T, Rosa AT (1974) A plasminogen proactivator-activator system in human blood effective in the absence of Hageman factor. Thromb Res 4: 609

  5. 5.

    Becker EL, Henson PM (1973) In vitro studies of immunologically induced secretion of mediators from cells and related phenomena. Adv Immunol 17: 93

  6. 6.

    Becker EL, Showell HJ, Henson PM, Hsu LS (1974) The ability of chemotactic factors to induce lysosomal enzyme release. I. The characteristics of the release, importance of surfaces, and the relation of enzyme release to chemotactic responsiveness. J Immunol 122: 2077

  7. 7.

    Becker S, Meuer S, Hadding U, Bitter-Suermann D (1978) Platelet activation: A new biological activity of guinea pig C3a-anaphylatoxin. Scand J Immunol 7: 173

  8. 8.

    Becker S, Hadding U, Schorlemmer HU, Bitter-Suermann D (1978) Demonstration of high-affinity binding sites for C3a-anaphylatoxin on guinea pig platelets. Scand J Immunol 8: 551

  9. 9.

    Beller FK, Mitchell P (1965) Production of the generalized Shwartzman reaction by protease inhibitors. Fed Proc 24: 155

  10. 10.

    Bianco C, Eden A, Cohn ZA (1976) The induction of macrophage spreading: Role of coagulation factors and the complement system. J Exp Med 144: 1531

  11. 11.

    Binder BR, Spragg J, Austen KF (1979) Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 254: 1998

  12. 12.

    Bokisch VA, Müller-Eberhard HJ, Cochrane CG (1969) Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 129: 1109

  13. 13.

    Campbell WD, Nelson RA (1973) Thrombin and complement: Lack of reactivity of purified bovine and human thrombin on components of the complement system. Immunol Commun 2: 473

  14. 14.

    Cezenave J-P, Assimeh SN, Painter RH, Packham MA, Mustard JF (1976) C1q inhibition of the interaction of collagen with human platelets. J Immunol 116: 162

  15. 15.

    Cheng CM, Hawiger J (1979) Affinity isolation and characterization of immunoglobulin G Fc fragment binding glycoprotein from human blood platelets. J Biol Chem 254: 2165

  16. 16.

    Chmielewska J, Poggi A, Janik P, Latallo ZS, Donati MB (1980) Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice. Eur J Cancer 16: 919

  17. 17.

    Cines DB, Schreiber AD (1979) Immune thrombocytopenia: Use of Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med 300: 106

  18. 18.

    Coleman RW (1969) Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 35: 273

  19. 19.

    Collen D (1980) On the regulation and control of fibrinolysis. Thromb Haemost 43: 77

  20. 20.

    Collen D (1980) Inhibitors of fibrinolysis. In: Kline DL, Reddy KNN (eds) Fibrinolysis. CRC Press, Boca Raton, Florida, p 129

  21. 21.

    Colten HR, Ooi YM, Edelson PJ (1979) Synthesis and secretion of complement proteins by macrophages. Ann NY Acad Sci 332: 482

  22. 22.

    Colten HR, Alper CA, Rosen FS (1981) Genetics and biosynthesis of complement proteins. N Engl J Med 304: 653

  23. 23.

    Colvin RB, Dvorak HF (1975) Role of the clotting system in cell-mediated hypersensitivity. II. Kinetics of fibrinogen/fibrin accumulation and vascular permeability changes in tuberculin and cutaneous basophil hypersensitivity reactions. J Immunol 114: 1377

  24. 24.

    Colvin RB, Mosesson MW, Dvorak HF (1979) Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest 63: 1302

  25. 25.

    Condie RM, Hong CV, Good RA (1957) Reversal of the lesion of the generalized Shwartzman phenomenon by treatment of rabbits with streptokinase. J Lab Clin Med 50: 803

  26. 26.

    Cooper NR, Miles LA, Griffin JH (1979) Activation of purified C1, the first component of complement by purified plasma kallikrein and plasmin. Thromb Haemost 42: 251

  27. 27.

    Cooper NR, Miles LA, Griffin JH (1980) Effects of plasma kallikrein and plasmin on the first complement component. J Immunol 124: 1517

  28. 28.

    Cooper NR, Miles LA, Griffin JH (to be published) Cleavage and activation of the first complement component by plasmin.

  29. 29.

    Corrigan JJ, Abilgaard CF, Vanderheiden JF, Schulman I (1967) Quantitative aspects of blood coagulation in the generalized Shwartzman reaction. Pediatr Res 1: 39

  30. 30.

    Cronlund M, Hardin J, Burton J, Lee L, Haber E, Bloch KJ (1976) Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus. J Clin Invest 58: 142

  31. 31.

    Curman B, Sandberg-Tragardh L, Peterson PA (1977) Chemical characterization of human Factor B of the alternative pathway of complement activation. Biochemistry 16: 5368

  32. 32.

    Curry MJ, Morrison DC (1979) Role of complement in endotoxin-mediated lethality in mice. Immunopharmacology 1: 125

  33. 33.

    Dahlback B, Stenflo J (1981) High molecular weight complex in human plasma between vitamin K-dependent Protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 78: 2512

  34. 34.

    Davidson JF, Nilsson JM, Astedt B Eds (1981) In: Progress in Fibrinolysis, Vol. 5. Churchill Livingstone, Edinburgh

  35. 35.

    Davie EW, Hanahan DJ (1977) Blood coagulation proteins. In: Putnam FW (ed) The plasma proteins, Vol. 3. Academic Press, New York, p 421

  36. 36.

    Dierich MP, Wilhelmi D, Till G (1977) Essential role of surface-bound chemoattractant in leukocyte migration. Nature 270: 351

  37. 37.

    DiScipio RG (1982) The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45: 587

  38. 38.

    Donaldson VH (1968) Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med 127: 411

  39. 39.

    Donaldson VH, Evans RR (1963) A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of C1-esterase. Am J Med 35: 37

  40. 40.

    Edgington TS, Levy GA, Schwartz BS, Fair DS (1981) A unidirectional pathway of lymphocyte-instructed macrophage and monocyte function characterized by the generation of procoagulant monokines. In: Weigle WO, Advances in immunopathology. Elsevier/North Holland, New York, p 173

  41. 41.

    Edwards RL, Rickles FR (1980) The role of monocyte tissue factor in the immune response. Lymphokine Reports 1: 181

  42. 42.

    Edwards RL, Rickles FR (1980) The role of human T cells and T cells products for monocyte tissue factor generation. J Immunol 125: 606

  43. 43.

    Edwards RL, Rickles FR, Bobrove AM (1979) Mononuclear cell tissue factor: Cell of origin and requirements for activation. Blood 54: 359

  44. 44.

    Fair D, Tsao B, Curtiss L, Edgington T (1983) Monocytes can be induced by lipopolysaccharide stimulated T cells to express Factor VII activity. Thromb Haemost 50: 172

  45. 45.

    Fair DS, Sundsmo JS, Schwartz BS, Edgington TS, Müller-Eberhard HJ (1981) Prothrombin activation by Factor B (Bb) of the alternative pathway of complement. Thromb Haemost 46: 301

  46. 46.

    Fearon DT, Austen KF (1980) The alternative pathway of complement — A system for host resistance to microbial infection. N Engl J Med 303: 259

  47. 47.

    Fey G, Colten HR (1981) The biosynthesis of complement proteins. Fed Proc 40: 2099

  48. 48.

    Fiedel BA, Gewurtz H (1980) Complement (C1q), polyanions and platelet activation. Thromb Res 19: 729

  49. 49.

    Forbes CD, Pensky J, Ratnoff OD (1970) Inhibition of activated Hageman factor and activated thromboplastin antecedent by purified C1 inactivator. J Lab Clin Med 76: 809

  50. 50.

    Fruton JS (1975) The specificity of proteinases toward protein substrates. In: Reich E, Rifkin DB, Shaw E Proteases and biological control. Cold Spring Harbor Laboratory, New York, p 33

  51. 51.

    Ghebrehewet B, Silverberg M, Kaplan AP (1981) Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153: 665

  52. 52.

    Gigli I, Mason JW, Colman RW, Austen KF (1970) Interactions of plasma kallikrein with C1 inhibitor. J Immunol 104: 574

  53. 53.

    Glovsky, MM, Hugli TE, Hartmann CT, Ghekiere L (1976) Possible role of C3a in human disease. In: Opferkuch W, Rother K, Schutz DR (eds) Clinical aspects of the complement system. George Thieme, Stuttgart, p 138

  54. 54.

    Goldstein IM, Perez HD (1980) Biologically active peptide derived from the fifth component of complement. Prog Hemost Thromb 5: 41

  55. 55.

    Gordon JL ed (1981) Platelets in biology and pathology 2. Elsevier/North Holland, New York

  56. 56.

    Graff KS, Leddy JP, Breckenridge RT (1976) Platelet function in man, a requirement for C5. J Immunol 116: 1735

  57. 57.

    Gramse M, Bingenheimer C, Schmidt W (1978) Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes. Characterization and effects on blood coagulation in vitro. J Clin Invest 61: 1027

  58. 58.

    Halbwachs L, Lachmann PJ (1976) Factor B of the alternative complement pathway on human lymphocytes. Scand J Immunol 5: 697

  59. 59.

    Harpel PC (1970) C1 inactivator inhibition by plasmin. J Clin Invest 49: 568

  60. 60.

    Harpel PC (1970) Human plasma α-2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med 132: 329

  61. 61.

    Hathaway WE, Alsever J (1970) The relation of ‘Fletcher factor’ to Factors XI and XII. Br J Haematol 18: 161

  62. 62.

    Henson PM (1969) Role of complement and leukocytes in immunologic release of vasoactive amines from platelets. Fed Proc 28: 1721

  63. 63.

    Henson PM (1970) Mechanisms of release of constituents from rabbit platelets by antigen-antibody complexes and complement. I. Lytic and non-lytic reactions. J Immunol 105: 476

  64. 64.

    Henson PM, Betz SJ (1980) In: Kelly WN, Harris ED, Ruddy, S, Sledge G. B. (eds) A textbook of rheumatology. Saunders Philadelphia, p 72

  65. 65.

    Henson PM, Ginsberg MH (1981) Immunological reactions of platelets. In: Gordon GL (ed) Platelets in biology and pathology 2. Elsevier/North Holland, New York, p 265

  66. 66.

    Henson PM, Pinckard RN (1977) Platelet-activating factor (PAF). A possible direct mediator of anaphylaxis in rabbits and a trigger for the vascular deposition of circulating immune complexes. Monogr Allergy 12: 13

  67. 67.

    Henson PM Spiegelberg HL (1973) Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses. J Clin Invest 52: 1282

  68. 68.

    Henson PM, McCarthy K, Larsen GL, Webster RO, Giclas PC, Dreisin RB, King TE, Shaw JO (1979) Complement fragments, alveolar macrophages and alveolitis. Am J Pathol 97: 93

  69. 69.

    Henson PM, Hollister JR, Musson RA, Webster RO, Spears P, Henson JE, McCarthy KM (1979) Inflammation as a surface phenomenon: Initiation of inflammatory processes by surface-bound immunologic components. Adv Inflam Res 1: 341

  70. 70.

    Heusinkveld RS, Leddy JP, Klemperer MR, Breckenridge RT (1974) Hereditary deficiency of the sixth component of complement in man. II. Studies of hemostasis. J Clin Invest 53: 554

  71. 71.

    Horowitz HI, Des Prez RM, Hook EW (1962) Effects of bacterial endotoxin on rabbit platelets. II. Enhancement of platelet factor 3 activity in vitro and in vivo. J Exp Med 116: 619

  72. 72.

    Hoylaertx M, Rijken DC, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257: 2912

  73. 73.

    Hugli TE (1977) Complement factors and inflammation: Effects of thrombin on components of C3 and C5. In: Lundblad RL, Fenton JW, Mann KG (eds). Chemistry and biology of thrombin. Ann Arbor Science Publishers, Michigan, p 345

  74. 74.

    Hugli TE (1981) The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. CRC Crit Rev Immunol 1: 321

  75. 75.

    Hugli TE (1981) Interrelationships between coagulation and complement activation. In: Fareed J, Messmore HL, Fenton JW, Brinkhous KM (eds) Perspectively in hemostasis. Pergamon Press, New York, p. 59

  76. 76.

    Jackson CM, Nemerson Y (1980) Blood coagulation. Annu Rev Biochem 49: 765

  77. 77.

    Jacob HS (1980) Complement-induced vascular leukostasis. Its role in tissue injury. Arch Pathol Lab Med 104: 617

  78. 78.

    Johnson U, Ohlsson K, Olsson I (1976) Effects of granulocyte neutral proteases on complement components. Scand J Immunol 5: 421

  79. 79.

    Kagan LJ, Leddy JP, Becker EL (1963) The presence of two permeability globulins in human serum. J Clin Invest 42: 1353

  80. 80.

    Kanyerezi B, Lwanga AK, Block KJ (1971) Fibrinogen degradation products in serum and urine of patients with systemic lupus erythematosus. Relation to renal disease and pathogenetic mechanisms. Arthritis Rheum 14: 267

  81. 81.

    Kaplan AP, Austen KF (1971) A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133: 696

  82. 82.

    Kaplan AP, Austen KF (1972) The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med 136: 1378

  83. 83.

    Kaplan AP, Goetzl EJ, Austen KF (1973) The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator. J Clin Invest 52: 2591

  84. 84.

    Kernbaum S, Bastin R, Wautier J-L, Bure A, Gougerot M, Peltier AP (1980) Human deficiency of the sixth component of complement in a patient with meningoccal meningitis and no haemostasis abnormality. Biomedicine 33: 197

  85. 85.

    Kleinmaier H, Goergen K, Lasch HG, Krecke HJ, Bohle A (1959) Studies on the problem of blood coagulation disorder in Sanarelli-Shwartzman phenomenon (so called generalized Shwartzman phenomenon of the rabbit). Z Ges Exptl Med 132: 275

  86. 86.

    Klinman A, McKay DG (1958) The prevention of the generalized Shwartzman reaction by fibrinolytic activity. Arch Pathol Lab Med 66: 715

  87. 87.

    Kondo M, Hosokawa K, Masuda M (1976) Cold activation of complement. I. Presence of coagulation-related activator. J Immunol 117: 486

  88. 88.

    Lachmann PJ, Thompson RA (1970) Reactive lysis: The complement mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification an C7. J Exp Med 131: 643

  89. 89.

    Lachmann PJ, Kay AB, Thompson R (1970) The chemotactic activity for neutrophil and eosinophil leucocytes of the trimolecular complex of the fifth, sixth, and seventh components of human complement (C5, 6, 7) prepared in free solution by the ‘reactive lysis’ procedure. Immunology 19: 895

  90. 90.

    Landerman NS, Webster ME, Becker EL, Ratcliff HE (1962) Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 33: 330

  91. 91.

    Lesavre PH, Müller-Eberhard HJ (1978) Mechanism of action of Factor D of the alternative complement pathway. J Exp Med 148: 1498

  92. 92.

    Laurell A-B, Lundh B, Malinquist J (1965) Inability of highly purified streptokinase preparations to inactivate complement in serum. Acta Microbiol Scand 64: 318

  93. 93.

    Lepow IH, Wurz L, Ratnoff OD, Pillemer L (1954) Studies on the mechanisms of inactivation of human complement by plasmin and by antigen-antibody aggregates. J Immunol 73: 146

  94. 94.

    Lepow IH, Ratnoff OD, Levy LR (1958) Studies on the activation of a proesterase associated with partially purified first component of complement. J Immunol 107: 451

  95. 95.

    Lerner RG, Rapaport SI, Siemsen JK, Spitzer JM (1968) Disappearance of fibrinogen-131 I after endotoxin: effects of a first and second injection. Am J Physiol 214: 532

  96. 96.

    Lerner RG, Goldstein R, Cummings G (1971) Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc Soc Exp Biol Med 138: 145

  97. 97.

    Levin J, Beck E (1966) A reappraisal of the role of blood coagulation and platelets in the generalized Shwartzman phenomenon. Thromb Diath Haemorrh 15: 519

  98. 98.

    Levy GA, Edgington TS (1980) Lymphocyte cooperation is required for amplification of macrophage procoagulant activity. J Exp Med 151: 1232

  99. 99.

    Levy GA, Schwartz BS, Edgington TS (1981) The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide. J Immunol 127: 357

  100. 100.

    Levy GA, Leibowitz JL, Edgington TS (1981) Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J Exp Med 154: 1150

  101. 101.

    Levy GA, Schwartz BS, Curtiss LK, Edgington TS (1981) Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. Requirements for cellular cooperation. J Clin Invest 67: 1614

  102. 102.

    Maillard JL, Favreau C (1981) Plasminogen activation by normal B lymphocytes, a function associated with the cell membrane. J Immunol 126: 1126

  103. 103.

    Mandle RJ, Kaplan AP (1977) Hageman factor substrates. Human plasma kallikrein: Mechanism of activation of Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 252: 6097

  104. 104.

    Martin SE, Breckenridge RT, Rosenfeld SI, Leddy JP (1978) Responses of human platelets to immunologic stimuli: Independent roles for complement and IgG in zymosan activation. J Immunol 120: 9

  105. 105.

    Marx JL (1982) Coagulation as a common thread in disease. Science 218: 145

  106. 106.

    Mason RG, Saba HI (1978) Normal and abnormal hemostasis — An integrated view. Am J Pathol 92: 775

  107. 107.

    McKay DG, Shapiro SS, Shanberge JN (1958) Alterations in the blood coagulation system induced by bacterial endotoxins. I. In vivo generalized Shwartzman reaction J Exp Med 107: 353

  108. 108.

    McKay DG, Shapiro SS, Shanberge JN (1958) Alterations in the blood coagulation system induced by bacterial endotoxins. II. In vitro. J Exp Med 107: 369

  109. 109.

    McManus LM, Hanahan DJ, Demopoulas CA, Pinckard RN (1980) Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic plateletactivating factor (PAF), in the rabbit. J Immunol 124: 2914

  110. 110.

    Menzel EJ, Smolen JS, Liotta L, Reid KBM (1981) Interaction of fibronectin with C1q and its collagen-like fragment (CLF). FEBS Lett 129: 188

  111. 111.

    Meuer S, Hugli TE, Andreatta RH, Hadding U, Bitter-Suermann, D (1981) Comparative study on biological activities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion. Inflammation 5: 275

  112. 112.

    Meuer S, Ecker U, Hadding U, Bitter-Suermann D (1981) Platelet serotonin release by C3a and C5a: Two independent pathways of activation. J Immunol 126: 1506

  113. 113.

    Meuth JL, Morgan EL, Hugli TE (1983) Inhibition of human T cell blastogenesis by a kallikrein cleavage fragment of human iC3b. Fed Proc 42: 566

  114. 114.

    Morrison DC, Cochrane CG (1974) Direct evidence for Hageman factor (Factor XII) activation by bacterial lipopolysaccharide. J Exp Med 140: 797

  115. 115.

    Morrison DC, Ulevitch RJ (1978) The effects of bacterial endotoxins on host mediation systems. Am J Pathol 93: 527

  116. 116.

    Morrison DC, Kline LF, Oades ZG, Henson PM (1978) Mechanisms of lipopolysaccharide-induced rabbit platelet responses: Alternative complement pathway dependence of the lytic response. Infect Immun 20: 744

  117. 117.

    Movat HZ, Mustard JF, Taichman NS, Uriuhara T (1965) Platelet aggregation and release of ADP, serotonin, and histamine associated with phagocytosis of antigen antibody complexes. Proc Soc Exp Biol Med 120: 232

  118. 118.

    Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI (1979) C5 chemotactic fragment induces leukocyte production of tissue factor activity. A link between complement and coagulation. J Clin Invest 63: 147

  119. 119.

    Müller-Eberhard HJ (1975) Complement. Annu Rev Biochem 44: 697

  120. 120.

    Mustard JF, Packham MA (1970) Factors influencing platelet function: Adhesion, release and aggregation. Pharmacol Rev 22: 97

  121. 121.

    Nagaki K, Fujikawa K, Inai S (1965) Studies of the fourth component of complement. II. The fourth component of complement in guinea pig and human platelets. Biken J 8: 129

  122. 122.

    Nelson LA, Rosenfeld SL, Leddy JP (1980) Properties of immune complexes mediating aggregation of human platelets. Arthritis Rheum 23: 725a

  123. 123.

    Nemerson Y, Furie B (1980) Zymogens and cofactors of blood coagulation. CRC Crit Rev Biochem 9: 45

  124. 124.

    Nesheim ME, Katzmann JA, Tracy PB, Mann KG (1981) Factor V. Methods Enzymol 80: 249

  125. 125.

    Niemetz J (1972) Coagulant activity of leukocytes. Tissue factor activity. J Clin Invest 51: 307

  126. 126.

    Niemetz J, Fani K (1971) Role of leukocytes in blood coagulation and the generalized Shwartzman reaction. Nature 232: 247

  127. 127.

    Oit FW, Varani J, Kreutzer DL, Senior RM, Ward PA (1979) Digestion of the fifth component of complement by leukocyte enzymes: Sequential generation of chemotactic activities for leukocytes and for tumor cells. Am J Pathol 94: 75

  128. 128.

    Østerud B, Lindahl V, Seljelid R (1980) Macrophages produce blood coagulation factors. FEBS Lett 120: 41

  129. 129.

    Østerud B, Bogwald J, Lindahl U, Seljelid R (1981) Production of blood coagulation Factor V and tissue thromboplastin by macrophages in vitro. FEBS Lett 127: 154

  130. 130.

    Pfueller SL, Luscher EF (1972) The effects of aggregated immunoglobulins on human blood platelets in relation to their complement-fixing abilities. J Immunol 109: 517

  131. 131.

    Pfueller SL, Luscher EF (1974) Studies of the mechanisms of human platelet release reaction induced by immunologic stimuli. I. Complement-dependent and complement-independent reactions. J Immunol 112: 1201

  132. 132.

    Pfueller SL, Luscher EF (1974) Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. II. The effect of zymosan. J Immunol 112: 1211

  133. 133.

    Pillemer L, Ratnoff OD, Bluf L, Lepow IH (1953) The inactivation of complement and its components by plasmin. J Exp Med 97: 573

  134. 134.

    Plow EF (1982) Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway. J Clin Invest 69: 564

  135. 135.

    Plow EF, Edgington TS (1975) An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 56: 30

  136. 136.

    Podack ER, Müller-Eberhard HJ (1980) Limited proteolysis of C5b-6: Functional stability of the degraded complex. J Immunol 124: 332

  137. 137.

    Polley MJ, Nachmann RL (1975) Ultrastructural lesions on the surface of platelets associated with either blood coagulation or with antibody-mediated immune injury. J Exp Med 141: 1261

  138. 138.

    Polley MJ, Nachman RL (1978) The human complement system in thrombin-mediated platelet function. J Exp Med 147: 1713

  139. 139.

    Polley MJ, Nachman RL (1979) Human complement in thrombin-mediated platelet function: Uptake of the C5b-9 complex. J Exp Med 150: 633

  140. 140.

    Polley MJ, Nachman RL, Weksler BB (1981) Human complement in the arachidonic acid transformation pathway in platelets. J Exp Med 153: 257

  141. 141.

    Prydz H, Allison AC, Schorlemmer HU (1977) Further link between complement activation and blood coagulation. Nature 270: 173

  142. 142.

    Prydz H, Lyberg T, Deteix P, Allison AC (1979) In vitro stimulation of tissue thromboplastin (Factor III) activity in human monocytes by immune complexes and lectins. Thromb Res 15: 465

  143. 143.

    Rapaport SI, Hjort PF (1967) The blood clotting properties of rabbit peritoneal leukocytes in vitro. Thromb Diath Haemorrh 17: 222

  144. 144.

    Ratnoff OD (1969) Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. Adv Immunol 10: 145

  145. 145.

    Ratnoff OD, Naff GB (1967) The conversion of C1s to C1 esterase by plasmin and trypsin. J Exp Med 125: 337

  146. 146.

    Ratnoff OD, Pensky J, Ogston D, Naff GB (1969) The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J Exp Med 129: 315

  147. 147.

    Reid KBM, Porter RR (1981) The proteolytic activation systems of complement. Annu Rev Biochem 50: 433

  148. 148.

    Rickles FR, Hardin JA, Pitlick FA, Hoyer LW, Conrad ME (1973) Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A. J Clin Invest 52: 1427

  149. 149.

    Rickles FR, Levin J, Hardin JA, Barr CF, Conrad ME (1977) Tissue factor generation by human mononuclear cells: Effects of endotoxin and disassociation of tissue factor generation from mitogenic response. J Lab Clin Med 89: 792

  150. 150.

    Rijken DC, Collen D (1980) Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 256: 7035

  151. 151.

    Rijken DC, Winjngaards G, Zaal-de Jong M, Welbergen J (1979) Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta 580: 140

  152. 152.

    Rijken DC, Winjngaards G, Welbergen J (1981) Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 97: 477

  153. 153.

    Rijken DC, Hoylaerts M, Collen D (1982) Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activators. J Biol Chem 257: 2920

  154. 154.

    Robbins J, Stetson CA (1959) An effect of antigen-antibody interaction on blood coagulation. J Exp Med 109: 1

  155. 155.

    Rodriguez-Erdmann F (1964) Studies on the pathogenesis of the generalized Shwartzman reaction. I. Alterations in the coagulation system during the generalized Shwartzman reaction of the pregnant rabbit. Thromb Diath Haemorrh 12: 452

  156. 156.

    Rodriguez-Erdmann F (1964) Studies on the pathogenesis of the generalized Shwartzman reaction. II. Role played by experimentally induced fibrinolysis. Thromb Diath Haemorrh 12: 462

  157. 157.

    Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC (1980) The role of phospholipids and Factor Va in the prothrombinase complex. J Biol Chem 255: 274

  158. 158.

    Ross GD (1982) Structure and function of membrane complement receptors. Fed Proc 41: 3089

  159. 159.

    Rothberger H, Zimmerman TS, Spiegelberg HL, Vaughan JH (1977) Leukocyte procoagulant activity: Enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest 59: 549

  160. 160.

    Salzman EW (1972) Cyclic AMP and platelet function. N Engl J Med 286: 358

  161. 161.

    Schorlemmer HU, Bitter-Suermann D, Allison AC (1977) Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. Immunology 32: 929

  162. 162.

    Schreiber AD, Kaplan AP, Austen KF (1973) Inhibition by C1 INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 52: 1402

  163. 163.

    Schreiber AD, Kaplan AP, Austen KF (1973) Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest 52: 1394

  164. 164.

    Schwartz BS, Edgington TS (1981) Immune complex-induced human monocyte procoagulant activity. I. A rapid unidirectional lymphocyte instructed pathway. J Exp Med 154: 892

  165. 165.

    Schwartz BS, Levy GA, Curtiss LK, Fair DS, Edgington TS (1981) Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. Two procoagulant activities are produced by peripheral blood mononuclear cells. J Clin Invest 67: 1650

  166. 166.

    Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, Hanahan DJ (1981) Activation of human neutrophils with 1-o-hexadecyl/octadecyl-2-acetyl-Sn-glycerol-3-phosphate (platelet-activating factor). J Immunol 127: 1250

  167. 167.

    Siraganian RP (1972) Platelet requirement in the interaction of complement and clotting systems. Nature 239: 208

  168. 168.

    Stetson CA (1951) The occurrence of leucocyte-platelet thrombosis in rheumatic carditis. J Exp Med 94: 493

  169. 169.

    Suba EA, Scako G (1976) C1q (C1) receptor on human platelets: Inhibition of collagen-induced platelet aggregation by C1q (c1) molecules. J Immunol 117: 304

  170. 170.

    Sumi H, Muramatu M, Jugii S (1973) The relation of C1s, a subunit of the activated first component of complement, to other plasma enzymes. Biochim Biophys Acta 327: 207

  171. 171.

    Sundsmo JS (1980) Expression of complement on human peripheral blood lymphocytes. Fed Proc 39: 1200

  172. 172.

    Sundsmo JS (1982) The leukocyte complement system. Fed Proc 41: 3094

  173. 173.

    Sundsmo JS, Fair DS (to be published) Leukocyte complement: A possible role for complement and Factor B in lymphocyte stimulation.

  174. 174.

    Sundsmo JS, Wood LM (1981) Activated Factor B (Bb) of the alternative pathway of complement cleaves and activates plasminogen. J Immunol 127: 877

  175. 175.

    Sundsmo JS, Curd JG, Kolb WP, Müller-Eberhard HJ (1978) Leukocyte complement: Assembly of the membrane attack complex of complement by human peripheral blood leukocytes in the presence and absence of serum. J Immunol 120: 855

  176. 176.

    Tack BF, Morris SC, Prahl JW (1979) Third component of human complement: Structural analysis of the polypeptide chains of C3 and C3b. Biochemistry 18: 1497

  177. 177.

    Tans G, Griffin JH (1982) Properties of sulfatides in Factor XII-dependent contact activation. Blood 59: 69

  178. 178.

    Taubman SB, Lepow IH (1971) Cleavage of human C1s by human lysosomal enzymes, plasmin, and trypsin. Immunochemistry 8: 951

  179. 179.

    Taylor FB, Müller-Eberhard HJ (1968) A qualitative description of factors involved in lysis of dilute whole blood clots. J Immunol 101: 820

  180. 180.

    Taylor FB, Müller-Eberhard HJ (1970) Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in aggregation and retraction of platelets. J Clin Invest 49: 2068

  181. 181.

    Taylor FB, Ward PA (1967) Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med 26: 149

  182. 182.

    Taylor JC, Crawford IP, Hugli TE (1977) Limited degradation of the third component (C3) of human complement by human leukocyte elastase (HLE): Partial characterization of C3 fragments. Biochemistry 16: 3390

  183. 183.

    Tenner AJ, Cooper NR (1980) Analysis of receptor-mediated C1q binding to human peripheral blood mononuclear cells. J Immunol 125: 1658

  184. 184.

    Thomas M, Good RA (1952) Studies on the generalized Shwartzman reaction. I. General observations concerning the phenomenon. J Exp Med 96: 605

  185. 185.

    Thompson RA, Rowe DS (1968) Reactive haemolysis — A distinct form of red cell lysis. Immunology 14: 745

  186. 186.

    Tomikawa M, Abiko Y (1973) The plasminogen-plasmin system. Part VIII. On the mechanism of chemical induction of fibrinolysis. Isolation of a latent plasminogen activator from human plasma. Thromb Diath Haemorrh 29: 50

  187. 187.

    Tsao B, Fair DS Curtiss LK, Edgington TS (to be published) Expression of Factor VII activity in lipopolysaccharide stimulated human peripheral mononuclear cells. Blood

  188. 188.

    Ulevitch RJ, Cochrane CG, Henson PM, Morrison DC, Doe WF (1975) Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med 142: 1570

  189. 189.

    Unkeless JD, Gordon S, Reich E (1974) Secretion of plasminogen activator by stimulated macrophages. J Exp Med 139: 834

  190. 190.

    van Ginkel CJW, van Aken WG (1980) Generation of tissue thromboplastin by human monocytes. In: van Furth R (ed) Mononuclear phagocytes: Functional aspects. Martinus Nijhoff Publishers, The Hague, p 1351

  191. 191.

    Vassali P, McCluskey RT (1976) The pathogenic role of coagulation process in glomerular diseases of immunologic origin. Adv Nephrol 1: 47

  192. 192.

    Venerrod AM, Laake K (1976) Prekallikrein and plasminogen proactivator: Absence of plasminogen proactivator in Fletcher factor deficient plasma. Thromb Res 8: 519

  193. 193.

    Venge P, Olsson I (1975) Cationic protein of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity. J Immunol 115: 1505

  194. 194.

    Wallen P, Kok P, Ranby M (1978) The tissue activator of plasminogen. In: Magnusson S, Ottegen M, Foltman B, Dano K, Neurath H (eds) Regulatory enzymes and their controls. Pergammon Press, Oxford, p 127

  195. 195.

    Ward PA (1967) A plasmin-split fragment of C3 as a new chemotactic factor. J Exp Med 126: 189

  196. 196.

    Ward PA, Cochrane CG, Müller-Eberhard HJ (1965) The role of serum complement in chemotaxis of PMN's. J Exp Med 122: 327

  197. 197.

    Wautier JL, Tobelem GM, Peltier AP, Caen JP (1974) Evidence for C1 on human platelets. Haemostasis 2: 281

  198. 198.

    Wautier JL, Tobelem GM, Peltier AP, Caen JP (1976) C1 and human platelets. II. Detection by immunological methods and role. Immunology 30: 459

  199. 199.

    Wautier JL, Sonchon H, Cohen-Solal L, Peltier AP, Caen JP (1976) C1 and human platelets. III. Role of C1 subcomponent in platelet aggregation induced by aggregated IgG. Immunology 31: 595

  200. 200.

    Wautier JL, Souchon H, Reid KBM, Peltier AP, Caen JP (1977) Studies on the mode of reaction of the first component of complement with platelets: Interaction between collagen-like portion of C1q and platelets. Immunochemistry 14: 763

  201. 201.

    Wautier JL, Reid KBM, Legrand Y, Caen JP (1980) Region of the C1q molecule involved in the interaction between platelets and the subcomponent C1q of the first component of complement. Mol Immunol 17: 1399

  202. 202.

    Wautier JL, Ollier-Hartmann MP, Kadeva H, Cohen F, Hartmann L, Caen JP (1981) First component of complement and thrombosis. Thromb Haemost 45: 247

  203. 203.

    Webster RO, Hong SR, Johnston RB, Henson PM (1980) Biological effects of the human complement fragments C5a and C5a desarg on neutrophil function. Immunopharmacology 2: 201

  204. 204.

    Webster RO, Zanolari B, Henson PM (1980) Neutrophil chemotaxis in response to surface bound human C5a. Exp Cell Res 129: 55

  205. 205.

    Weigle WO, Morgan EL, Goodman MG, Chenoweth DE, Hugli TE (1982) Modulation of the immune response by anaphylatoxin in the microenvironment of the interacting cells. Fed Proc 41: 3099

  206. 206.

    Weissmann G, Samuelsson B, Paoletti R, Eds (1979) Advances in inflammation research. Raven Press, New York

  207. 207.

    Weksler BB, Coupal CE (1973) Platelet-dependent generation of chemotactic activity in serum. J Exp Med 137: 1419

  208. 208.

    Wiggins RC, Giclas PC, Henson PM (1981) Chemotactic activity generated from the fifth component of complement by plasma kallikrein of rabbit. J Exp Med 153: 1391

  209. 209.

    Wiman B, Collen D (1978) Molecular mechanism of physiological fibrinolysis. Nature 272: 549

  210. 210.

    Woolridge D, Spragg J, Austen KF (1974) Interaction of Hageman factor-dependent systems with the complement sequence. In: Pisano JJ, Austen KF (eds) Chemistry and biology of the kallikreinkinin systems in health and disease. National Institute of Health Monograph, Bethesda, p 221

  211. 211.

    Wright PG, Gallin JJ (1977) A functional differentiation of human neutrophil granules: Generation of C5a by a specific (secondary) granule product and inactivation of C5a by azurophil (primary) granule products. J Immunol 119: 1068

  212. 212.

    Wuepper KD (1972) Biochemistry and biology of components of the plasma kinin-forming system. In: Lepow IH, Ward PA (eds) Inflammation mechanisms and control. Academic Press, New York, p 93

  213. 213.

    Ziccardi RJ (1982) Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. J Immunol 128: 2500

  214. 214.

    Ziccardi RJ (1982) A new role of C1-inhibitor in homeostasis: Control of activation of the first component of human complement. J Immunol 128: 2505

  215. 215.

    Zimmerman TS (1976) The coagulation mechanism and the inflammatory response. In: Miescher PA, Müller-Eberhard HJ (eds) Textbook of immunopathology. Grune and Stratton, New York, p 95

  216. 216.

    Zimmerman TS, Kolb WP (1976) Human platelet-initiated formation and uptake of the C5–9 complex of human complement. J Clin Invest 57: 203

  217. 217.

    Zimmerman TS, Müller-Eberhard HJ (1971) Blood coagulation initiation by complement-mediated pathway. J Exp Med 134: 1601

  218. 218.

    Zimmerman TS, Arroyave CM, Müller-Eberhard HJ (1971) A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med 134: 1591

  219. 219.

    Zimmerman TS, Fierer J, Rothberger H (1977) Blood coagulation and the inflammatory response. Semin Hematol 14: 391

  220. 220.

    Zucker MB, Grant RA (1974) Aggregation and release reaction induced in human blood by zymosan. J Immunol 112: 1219

  221. 221.

    Zucker MB, Grant RA, Alper CA, Goodkofsky I, Lepow IH (1974) Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets. J Immunol 113: 1744

Download references

Author information

Additional information

This is publication number 2961 from the Research Institute of Scripps Clinic

The investigators are supported by the United States Public Health Service grants # R01-AI-17890, R01-HL-28672, HL-16411-08, and a grant from the Eli Lilly Co.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sundsmo, J.S., Fair, D.S. Relationships among the complement, kinin, coagulation, and fibrinolytic systems. Springer Semin Immunopathol 6, 231–258 (1983). https://doi.org/10.1007/BF00205875

Download citation

Keywords

  • Internal Medicine
  • Fibrinolytic System